Kailera Therapeutics, Inc. Common Stock (NASDAQ:KLRA) — Market Cap & Net Worth
Market Cap & Net Worth: Kailera Therapeutics, Inc. Common Stock (KLRA)
Kailera Therapeutics, Inc. Common Stock (NASDAQ:KLRA) has a market capitalization of $2.54 Billion ($2.54 Billion) as of July 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5507 globally and #1772 in its home market, demonstrating a 2.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kailera Therapeutics, Inc. Common Stock's stock price $21.99 by its total outstanding shares 129565608 (129.57 Million). Review Kailera Therapeutics, Inc. Common Stock (KLRA) total liabilities to assess the company's total debt and financial obligations.
Kailera Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Kailera Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $2.85 Billion to $2.85 Billion (0.00% CAGR).
Kailera Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kailera Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLRA by Market Capitalization
Companies near Kailera Therapeutics, Inc. Common Stock in the global market cap rankings as of July 7, 2026.
Key companies related to Kailera Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #431 globally with a market cap of $64.60 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #570 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $528.04 |
| #431 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $654.27 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €259.50 |
| #570 | Argen-X | BR:ARGX | $47.14 Billion | €830.80 |
Kailera Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Kailera Therapeutics, Inc. Common Stock's market cap moved from $2.85 Billion to $ 2.85 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 6th, 2026 the market cap of Kailera Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.54 Billion USD |
| MoneyControl | $2.54 Billion USD |
| MarketWatch | $2.54 Billion USD |
| marketcap.company | $2.54 Billion USD |
| Reuters | $2.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more